Amandeep Khurana, MD
Nephrology · Phoenix, AZNPI 1508852716
Payments from drug & device makers
Across 95 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$300
- AstraZeneca$296
- Akebia Therapeutics Inc$134
- Vantive US Healthcare LLC$128
- Travere Therapeutics, Inc.$123
- Boston Scientific$121
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,16798%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 17 | $300 |
| AstraZeneca(2 entities) | 15 | $296 |
| Akebia Therapeutics Inc | 6 | $134 |
| Vantive US Healthcare LLC | 1 | $128 |
| Travere Therapeutics, Inc. | 5 | $123 |
| Boston Scientific | 1 | $121 |
| Bayer | 7 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $108 |
| Veloxis Pharmaceuticals, Inc. | 3 | $107 |
| Daiichi Sankyo Inc. | 4 | $99 |
| Boehringer Ingelheim | 3 | $75 |
| Abbott | 2 | $72 |
| Merck | 2 | $59 |
| OPKO Pharmaceuticals, LLC | 3 | $56 |
| GSK | 4 | $53 |
| Novartis | 2 | $43 |
| Ardelyx, Inc. | 2 | $42 |
| Vifor Pharma, Inc. | 2 | $37 |
| Calliditas Therapeutics US Inc. | 1 | $31 |
| Vanda Pharmaceuticals Inc. | 2 | $25 |
| Cormedix Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Nxstage Medical, Inc. | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELUVIA$121
How this compares
$2,203 in reported general payments places this provider in the 45th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluconazole | 68 | $3,970 |
| Mycophenolate Mofetil | 11 | $3,640 |
| Calcitriol | 64 | $1,448 |
| Allopurinol | 43 | $1,098 |
| Hydralazine Hcl | 51 | $851 |
| Tamsulosin Hcl | 51 | $815 |
| Losartan Potassium | 41 | $413 |
| Lisinopril | 48 | $406 |
| Prednisone | 47 | $393 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $371 |
| Chlorthalidone | 13 | $350 |
| Atorvastatin Calcium | 16 | $285 |
| Amlodipine Besylate | 46 | $261 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 17 | $137 |
| Hydrochlorothiazide | 16 | $129 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Phoenix
- Leslie ThomasPhoenix$3.1M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Hassan HachemPhoenix$372K
- Sungchun LeePhoenix$341K
- Shouwen WangPhoenix$195K
- Nina PatelPhoenix$174K
- Yuzana ZawPhoenix$159K
- Alexander NimriPhoenix$133K
- Samer Bani HaniPhoenix$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.